CorMedix Inc (CRMD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.95 is considered Undervalued compared with the five-year average of -4.43. The fair price of CorMedix Inc (CRMD) is between 63.77 to 72.09 according to relative valuation method. Compared to the current price of 7.21 USD , CorMedix Inc By Undervalued By 88.69%.

Relative Value

Fair Zone

63.77-72.09

Current Price：7.21

88.69%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is CorMedix Inc (CRMD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

CorMedix Inc (CRMD) has a current Price-to-Book (P/B) ratio of 2.55. Compared to its 3-year average P/B ratio of 5.10, the current P/B ratio is approximately -50.02% higher. Relative to its 5-year average P/B ratio of 4.24, the current P/B ratio is about -39.94% higher. CorMedix Inc (CRMD) has a Forward Free Cash Flow (FCF) yield of approximately 7.77%. Compared to its 3-year average FCF yield of -10.43%, the current FCF yield is approximately -174.47% lower. Relative to its 5-year average FCF yield of -11.48%, the current FCF yield is about -167.66% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CRMD competitors is 69.03, providing a benchmark for relative valuation. CorMedix Inc Corp (CRMD.O) exhibits a P/S ratio of 1.95, which is -97.17% above the industry average. Given its robust revenue growth of 810.22%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CRMD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CRMD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CRMD currently overvalued or undervalued?

What is CorMedix Inc (CRMD) fair value?

CRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of CorMedix Inc (CRMD) is between 63.77 to 72.09 according to relative valuation method.

How does CRMD's valuation metrics compare to the industry average?

The average P/S ratio for CRMD's competitors is 69.03, providing a benchmark for relative valuation. CorMedix Inc Corp (CRMD) exhibits a P/S ratio of 1.95, which is -97.17% above the industry average. Given its robust revenue growth of 810.22%, this premium appears sustainable.

What is the current P/B ratio for CorMedix Inc (CRMD) as of Mar 03 2026?

As of Mar 03 2026, CorMedix Inc (CRMD) has a P/B ratio of 2.55. This indicates that the market values CRMD at 2.55 times its book value.

What is the current FCF Yield for CorMedix Inc (CRMD) as of Mar 03 2026?

As of Mar 03 2026, CorMedix Inc (CRMD) has a FCF Yield of 7.77%. This means that for every dollar of CorMedix Inc's market capitalization, the company generates 7.77 cents in free cash flow.

What is the current Forward P/E ratio for CorMedix Inc (CRMD) as of Mar 03 2026?

As of Mar 03 2026, CorMedix Inc (CRMD) has a Forward P/E ratio of 4.34. This means the market is willing to pay $4.34 for every dollar of CorMedix Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for CorMedix Inc (CRMD) as of Mar 03 2026?

As of Mar 03 2026, CorMedix Inc (CRMD) has a Forward P/S ratio of 1.95. This means the market is valuing CRMD at $1.95 for every dollar of expected revenue over the next 12 months.

CRMD Valuation